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Abstract
 Objective
Homocystinuria is a neurometabolic diseases characterized by symptoms 
include Neurodevelopmental delay, lens dislocation, long limbs and thrombosis. 
Materials & Methods
The patients who were diagnosed as homocystinuria marfaniod habits, seizure 
in the Neurology Department of Mofid Children’s Hospital in Tehran, Iran 
between 2004 and 2014 were included in our study. The disorder was confirmed 
by clinical andneuroimaging findings along withneurometabolic and genetic 
assessment fromreference laboratory in Germany. We assessed age, gender, past 
medical history, developmental status, clinical manifestations, and neuroimaging 
findings of 20 patients with homocystinuria. 
Results
A total of 75% of patients were offspring from consanguineous marriages. A 
total of 95% of patients had a history of developmental delay and 40% had 
developmental regression. A total of 75% had seizures from these 45% showed 
refractory seizures. Seizures among 13 patients werecontrolled with suitable 
homocystinuria treatment. The patients with homocystinuriawere followed for 
approximately 10 years and the follow-ups showed that the patients with an early 
diagnosis and treatment had more favorable clinical responses for growth index, 
controlled refractory seizures, neurodevelopmental status, and neuroimaging 
findings. Neuroimaging findings include brain atrophy and/or white matter 
involvement.
Conclusion
According to the results of this study, we suggest that early assessment and 
detectionplayan important role in the prevention of disease progression and 
clinical signs. Homocystinuria in patients with a positive family history, 
developmental delays, or regression, refractory, or recurrent seizures should take 
precedence over other causes.
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Introduction
Homocystine is an amino acid with sulfur that comes from methionine 
metabolism. Homocystineis metabolized by two pathways as follows: 
transsulfuration or remethylation (1). Gene abnormalities in the enzymes, which 
catalyze the reactions in trans sulfuration or remethylation pathways, can cause
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hyper homocysteinuria. Homocystinuria can be 
caused by abnormal DNA methylation during 
embryogenesis(2). Hyperhomocystinuria is 
causedbya rare genetic error causedby deficiencies in 
methylenetetrahydrofolate reductase, cystathionine 
beta synthase, or in enzymes involved in homocystine 
methylation andmethyl-B12 synthesis(3). There is an 
association between mutations of elevated levels of 
homocysteine, methylenetetrahydrofolate reductase, 
MTHFR C677T, and increased risk of thrombosis 
among homozygous carriers. Heterozygote carriers for 
the above gene mutations with other major or minor 
risk factors are prone to thrombosis (4).Mutation of 
the methylenetetrahydrofolate reductase (MTHFR) 
and provides the folate derivative for homocystine 
to methionine conversion. This mutation can cause 
mild hyperhomocysteinuria. The rationale (folate 
supplementation) can be usedto over come the genetic 
deficiency in cases with low levels of folate(5). High 
levels of homocystine in plasma are one of the risk 
factors for atherosclerosis (6).It has been showed 
that early detection and treatment can be helpful and 
homocystine levels can be controlled by vitamins B6, 
B12, cofactors needed for homocystine metabolism, 
and by folic acid supplements (7-9).
In this study, we present 10 years of experience about 
homocystinuria fromthe Pediatric Neurology Research 
Center of Mofid Children’s Hospital, Tehran, Iran. We 
describe clinical symptoms and neuroimaging findings 
for20 cases with this disorder.
Materials & Methods
This observational study was performed on patients 
who were diagnosed with homocystinuria at the 
Neurology Department of Mofid Children’s Hospital 
in Tehran, Iran, from2004–2014. The diagnosis 
was performed based on clinical manifestations, 
neuroimaging findings, homocystine level assessments 
in Germany,and,finally,genetic study. The data collected 
wereage, gender, past medical history, developmental 
status, general appearance, and clinical and neuroimaging 
findings.
Treatment consisted of betaine, carnitine, folic acid, 
vitamin B12, vitamin B6 supplements, a low-protein 
diet, and anti-convulsant drugs in cases with seizures. 
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The children’s diet was carefully controlled. The data 
were analyzed by descriptive methods and no statistical 
testing was applied.
Institutional ethical approval for the conduct of this study 
was obtained from the Pediatric Neurology Research 
Center of Shahid Beheshti University of Medical 
Sciences, Tehran, Iran. All parents signed a written 
consent for participation in the study.
Results
Twenty patients with homocystinuria who hadbeen 
assessed and followed over thelast 10 years were included 
in this study. Sixpatients,in addition tohomocysteinuria, 
had methylmalonicacidemia. There were 11 males and 
9 females with an agerangefrom 6-months to 15-years. 
The earliest case was diagnosed in a neonate who 
presented with a sepsis-like illness and the latest case 
was diagnosed in a 10 year-old with seizures due to 
cerebral thrombosis after lens dislocation surgery. The 
average age of patients at final detection time was9.6 
months. A total of 75% of patients were offspring from 
consanguineous marriages. In addition, 5 patients had a 
positive family history of similar disease and2 of them 
died without diagnosis.
One of our patients (39 months old) died about 2years 
after detection.The patient had not received any treatment 
due to his parent’s decision. 
Four patients had a history of neonatal hospitalization 
because of poor feeding in patient-number 1, was 
diagnosed at that time, and treatment of homocystinuria 
was started.Patient-number 2 had continuous 
vomiting that was permanent until 4 months of age 
and homocystinuria was detected at this time.Patient-
number 3 had sepsis-like illness from12 days of age but 
was diagnosed at 9 months of age. Patient-number 4 had 
a neonatal hospitalization due to hyper bilirubinemia.
The chief complaints in patients at detection time 
were seizures in 11 patients and developmental 
delays or regression in 7. Twocases had visual loss. 
In the developmental assessment, 19 patients had 
developmental delay, 8 patients had developmental 
regressions with words and movements stuck more 
than their recognition. Fifteen patients had seizures of 
which 9 patients had recurrent and refractory. The types 
of seizures were as follows:5 patients had generalized 
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Discussion
Homocystinuria is a rare inborn error of the 
metabolismwith autosomal recessive inheritance that 
is caused byenzyme deficiencies(3). Homocystinuria is 
caused by genetic mutations in the enzymes and may 
contribute to increases in plasma homocystine. First, 
Carson and Neill reported the association between 
mental retardationand homocystinuria in two Irish 
brothers in 1962 (10). In 1964, Gerritsen and Waisman 
first identified homocystine in the urine and defined 
homocystinuria (11). Prior to the 1960s, in 1933, 
homocystinuria had already been described in an eight-
year-old child with mental retardation, dislocation of the 
lens, and skeletal abnormalities with coxavara and who 
died from a stroke (12). Homocystinuria was diagnosed 
in this child’s nephew in 1965 (13). Normal levels of 
plasma homocysteine are between 5–15 nmol/ml and 
concentrations between 16–30 nmol/ml is mild, 31-
100nmol/ml is moderate, and greater than100 nmol/
ml is severe hyperhomocystinuria(14). MuddSHet 
al reported that around half of their cases had a good 
laboratory and clinical response to high doses of vitamin 
B6 (15). Fonseca et al had no known relevant clinical 
findings in family members (16). Treatment for elevated 
homocystine levels is simple and innocuous. High doses 
of pyridoxine (B6) were used initially with success in 
children with homocystinuria (17).
The clinical features include subluxation of the lens, 
which are characteristic for connective tissue disorders 
(15). Our results were similar and five patients had 
visual loss from lens dislocation and secondary 
cataracts. Twenty patients (11 males and 9 females) 
with homocystinuria were included in this study. 
A total of 75% of cases were fromconsanguineous 
parents and 25% had similar diseases in their families.
Therefore, in suspected cases of homocysteinuria, 
having consanguineous parents can contribute to the 
diagnosis because of autosomal recessive inheritance 
of homocysteinuria. A total of 15% of patients had 
a history of hospitalization due to period of sepsis-
like illness that metabolic disease assessment can be 
helpful indetection forill neonates. A total of 95% 
of patients had a history of developmental delay and 
40% had developmental regression. Patients with these 
symptoms who are referred to a pediatric neurologist, 
tonic clonic seizures; 5 had tonic seizures; 3 had partial 
seizures; and 2 patients had infantile spasms. The body 
weightof4 patients was below the 3rd percentile and the 
height in 6 patients wasabove the 5th percentile.Three 
patients had microcephaly but another patient was in 
thenormal developmental index. Three patients had 
erythematous scaling lesions on their skin. One patient 
had alopecia and 4 patients with homocystinuria had 
blond hairs and light eyes. Five patients had visual loss 
due to lens dislocation and secondary cataracts.One 
patient hadstrabismus and another patient had optic 
atrophy. Two patients had valvular heart disease. Seven 
patients had central hypotonicity . Two patients indicated 
stroke episodes. Six patients showed long fingers and 
long limbs.
The lab data showed that all patients had increased 
levels of homocystine in their serum (from 48–1022 
with maximum normal range of 16);6 patients had 
anemia;and 4 patients had megaloblastic anemia. These 
patients also had methylmalonicacidemia. Serum amino 
acid was assessedwiththe HPLC method and was 
showed elevated levels of glutamine in all patients, as 
well as increases in a few nonspecific aminoacids in 
some of the patients.
From the neuroimaging data, we saw that 11 patients had 
brain atrophyand white matter involvement;4 patients 
exhibited corpus callosum atrophy; 2 patients had only 
white matter involvement; 4 patients had a previous 
stroke; 1 patient had cerebral thrombosis; and 1patient 
had a normal brain MRI ( Figure 1).
Genetic analysis was done on 3 patients and reported 
mutant polymorphism of C677T heterozygote and 
mutant allele of C homozygote.
Patients were treated with a low protein diet, betaine, 
carnitine, folic acid, vitamin B12, vitamin B6, and anti-
convulsant drugs in cases with seizure. Seizures were 
controlled in13 patients after starting anti-convulsant 
drugs. Regression in our patients was stopped after 
starting treatment with 5 out of 8 patients progressed to 
have the ability again.Even white matter involvement 
and brain atrophy improved after treatment. Also 
further strokes after treatment did not occur. Only one 
patient who was 39 months old did not receive special 
treatment anddied due to a refractory seizure.
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it is our suggestion to for the pediatric neurologist to 
consider homocysteinuria. A total of 35% of patients 
had heights greater than normal and 40% of patients 
had skin and hair involvement, i.e. skin lesions and 
blond hair, among others.
From brain MRIs, 75% of patients had brain 
involvement (generalized atrophy, white matter 
involvement, previous infarct pattern, and venous sinus 
thrombosis). In follow-up imaging, which was done in 
6 patients, 50% of them had improvements in white 
matter involvement and brain atrophy. Sachdeva Vet 
al reported that all patients had ischemic lesions in the 
brain MRI with contrast (18).
A total of 75% of patients had seizures and 45% of these 
seizures werere current and refractory. Seizures were 
controlled for13 patients after starting anti-epileptic 
drugs and special treatment for homocysteinuria. 
Regression in our patients was stopped after starting 
treatment and 62% of patients regained that ability.In 
addition, further strokes after treatment did not occur.
Our patients with homocystinuria came to our specialist 
center and exact evaluationswere done. 
In conclusion, based on our results, patients with 
developmental delay or regression, long limbs and 
tall, recurrent seizures, skin lesions, blond hair, eye 
involvement such as secondary cataracts due to lens 
dislocation, hypotonia, brain involvement in MRI 
include brain atrophy or white matter involvement, 
and having a positive family history of homocystinuria 
thenhomocystinuria disorder should be considered. 
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Fig 1.  A-15-year –old male with brain involvement due to Homocystinuria
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